Charles River Laboratories Market Cap ($12.77 Billion)
Market Cap & Net Worth: Charles River Laboratories (CRL)
Charles River Laboratories market cap. Charles River Laboratories (NYSE:CRL) has a market capitalization of $12.77 Billion ($12.77 Billion) as of November 1, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #1785 globally and #689 in its home market, demonstrating a 5.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Charles River Laboratories's stock price $359.41 by its total outstanding shares 47738872 (47.74 Million). Also see Charles River Laboratories cash conversion from operations for how efficiently the company converts equity into cash flow.
Charles River Laboratories Market Cap History (2015–2026)
Charles River Laboratories market cap history from 2015 to 2026. Data shows growth from $3.84 Billion to $17.16 Billion (16.40% CAGR). Check today's stock price for Charles River Laboratories for real-time trading data and today's change.
Index Memberships
Charles River Laboratories is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 1.11% | #12 of 39 |
|
S&P 500 Index
GSPC
|
$61.47 Trillion | 0.01% | #427 of 503 |
Weight: Charles River Laboratories's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Charles River Laboratories Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Charles River Laboratories's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CRL year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.37x
Charles River Laboratories's market cap is 2.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.64 Billion | $1.68 Billion | $154.76 Million | 2.16x | 23.50x |
| 2017 | $5.23 Billion | $1.86 Billion | $123.36 Million | 2.81x | 42.36x |
| 2018 | $5.40 Billion | $2.27 Billion | $226.37 Million | 2.38x | 23.87x |
| 2019 | $7.29 Billion | $2.62 Billion | $252.02 Million | 2.78x | 28.94x |
| 2020 | $11.93 Billion | $2.92 Billion | $364.30 Million | 4.08x | 32.74x |
| 2021 | $17.99 Billion | $3.54 Billion | $390.98 Million | 5.08x | 46.00x |
| 2022 | $10.40 Billion | $3.98 Billion | $486.23 Million | 2.62x | 21.39x |
| 2023 | $11.29 Billion | $4.13 Billion | $474.62 Million | 2.73x | 23.78x |
| 2024 | $8.81 Billion | $4.05 Billion | $10.30 Million | 2.18x | 855.84x |
| 2025 | $9.52 Billion | $4.02 Billion | -$144.34 Million | 2.37x | N/A |
Competitor Companies of CRL by Market Capitalization
Companies near Charles River Laboratories in the global market cap rankings as of November 1, 2026. Also see balance sheet size of Charles River Laboratories for a full breakdown of the balance sheet.
Key companies related to Charles River Laboratories by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Charles River Laboratories (2015–2026)
Market capitalization of Charles River Laboratories from 2015 to today. Between 2015 and today, Charles River Laboratories's market cap moved from $3.84 Billion to $ 17.16 Billion, with a yearly change of 16.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $17.16 Billion | +80.17% |
| 2025 | $9.52 Billion | +8.06% |
| 2024 | $8.81 Billion | -21.91% |
| 2023 | $11.29 Billion | +8.49% |
| 2022 | $10.40 Billion | -42.17% |
| 2021 | $17.99 Billion | +50.80% |
| 2020 | $11.93 Billion | +63.56% |
| 2019 | $7.29 Billion | +34.97% |
| 2018 | $5.40 Billion | +3.41% |
| 2017 | $5.23 Billion | +43.65% |
| 2016 | $3.64 Billion | -5.22% |
| 2015 | $3.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Charles River Laboratories was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.77 Billion USD |
| MoneyControl | $12.77 Billion USD |
| MarketWatch | $12.77 Billion USD |
| marketcap.company | $12.77 Billion USD |
| Reuters | $12.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more